Nineteen patients with clinical and mammographic diagnosis of breast cancer and 1 patient already mastectomized underwent radioimmunoscintigraphy (RIS) in order to evaluate the axillary node status before surgery. After histologic examination, ductal breast carcinomas were found in 17/19 patients and axillary metastases were found in 11 patients. RIS was performed with planar scintigraphies and SPET (Single Photon Emission Tomography) of mammary and axillary regions after intravenous injection of In-111 B72.3. Overall RIS sensitivity for breast tumors was 71% (12/17); according to the tumor site different RIS sensitivity was demonstrated (90% for lesions of external quadrants versus 43% for lesions of internal quadrants). RIS was negative in 2 patients with post-surgery diagnosis of mammary dysplasia. As regards axillary metastasis RIS sensitivity and specificity were 91% (10/11) and 78% (7/9), respectively. Human Anti-Murine Antibody (HAMA) production was shown in 16.7% (2/12) of the patients. The quantitation of In-111 B72.3 uptake (%I.D./g; mean+/-S.D.) was 0.0054+/-0.0021 in breast tumors, 0.0021+/-0.0011 in normal mammary tissue, 0.0053+/-0.0027 in axillary metastasis and 0.0032+/-0.008 in normal axillary nodes. Our data demonstrated that RIS can detect tumor spread to the axilla in patients with breast cancer. Larger pre-operative study is required to evaluate if RIS can alter the management of this disease.
PRELIMINARY-RESULTS OF PREOPERATIVE AXILLARY RADIOIMMUNOSCINTIGRAPHY WITH IN-111 B72.3 IN BREAST-CANCER
CHITI A;
1995-01-01
Abstract
Nineteen patients with clinical and mammographic diagnosis of breast cancer and 1 patient already mastectomized underwent radioimmunoscintigraphy (RIS) in order to evaluate the axillary node status before surgery. After histologic examination, ductal breast carcinomas were found in 17/19 patients and axillary metastases were found in 11 patients. RIS was performed with planar scintigraphies and SPET (Single Photon Emission Tomography) of mammary and axillary regions after intravenous injection of In-111 B72.3. Overall RIS sensitivity for breast tumors was 71% (12/17); according to the tumor site different RIS sensitivity was demonstrated (90% for lesions of external quadrants versus 43% for lesions of internal quadrants). RIS was negative in 2 patients with post-surgery diagnosis of mammary dysplasia. As regards axillary metastasis RIS sensitivity and specificity were 91% (10/11) and 78% (7/9), respectively. Human Anti-Murine Antibody (HAMA) production was shown in 16.7% (2/12) of the patients. The quantitation of In-111 B72.3 uptake (%I.D./g; mean+/-S.D.) was 0.0054+/-0.0021 in breast tumors, 0.0021+/-0.0011 in normal mammary tissue, 0.0053+/-0.0027 in axillary metastasis and 0.0032+/-0.008 in normal axillary nodes. Our data demonstrated that RIS can detect tumor spread to the axilla in patients with breast cancer. Larger pre-operative study is required to evaluate if RIS can alter the management of this disease.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
